There is increasing evidence that oncogenic transformation modifies the metabolic program of cells. A common alteration is the upregulation of glycolysis, and efforts to target glycolytic enzymes for anticancer therapy are under way. Here, we performed a genome-wide haploid genetic screen to identify resistance mechanisms to 3-bromopyruvate (3-BrPA), a drug candidate that inhibits glycolysis in a poorly understood fashion. We identified the SLC16A1 gene product, MCT1, as the main determinant of 3-BrPA sensitivity. MCT1 is necessary and sufficient for 3-BrPA uptake by cancer cells. Additionally, SLC16A1 mRNA levels are the best predictor of 3-BrPA sensitivity and are most elevated in glycolytic cancer cells. Furthermore, forced MCT1 expression in 3-BrPAresistant cancer cells sensitizes tumor xenografts to 3-BrPA treatment in vivo. Our results identify a potential biomarker for 3-BrPA sensitivity and provide proof of concept that the selectivity of cancer-expressed transporters can be exploited for delivering toxic molecules to tumors.
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There is increasing evidence that oncogenic transformation modifies the metabolic program of cells. A common alteration is the upregulation of glycolysis, and efforts to target glycolytic enzymes for anticancer therapy are under way. Here, we performed a genome-wide haploid genetic screen to identify resistance mechanisms to 3-bromopyruvate (3-BrPA), a drug candidate that inhibits glycolysis in a poorly understood fashion. We identified the SLC16A1 gene product, MCT1, as the main determinant of 3-BrPA sensitivity. MCT1 is necessary and sufficient for 3-BrPA uptake by cancer cells. Additionally, SLC16A1 mRNA levels are the best predictor of 3-BrPA sensitivity and are most elevated in glycolytic cancer cells. Furthermore, forced MCT1 expression in 3-BrPAresistant cancer cells sensitizes tumor xenografts to 3-BrPA treatment in vivo. Our results identify a potential biomarker for 3-BrPA sensitivity and provide proof of concept that the selectivity of cancer-expressed transporters can be exploited for delivering toxic molecules to tumors.
As a result of the rewiring of small-molecule metabolism that accompanies oncogenic transformation, cancer cells acquire metabolic liabilities not shared by their normal counterparts [1] [2] [3] [4] . There is great interest in identifying these liabilities and exploiting them for the development of new cancer-selective therapies 5 . Many cancer cells activate aerobic glycolysis and so have high rates of glucose uptake and lactate excretion, even when oxygen is available for oxidative phosphorylation 6 . Several glycolytic enzymes, as well as the transporters that import glucose and export lactate, are considered targets for drug development [7] [8] [9] [10] [11] [12] [13] . We undertook a loss-of-function genetic screen to identify genes that affect the sensitivity of cancer cells to 3-BrPA, a drug candidate under clinical development 14, 15 . 3-BrPA has cytotoxic effects and decreases cellular energy levels by inhibiting glycolysis in a poorly understood fashion 16 . In addition to targeting glycolytic enzymes [17] [18] [19] , 3-BrPA can also inhibit several non-glycolytic enzymes [20] [21] [22] [23] [24] and, given its simple structure, is likely to have more than one direct protein target within cells. Thus, 3-BrPA is probably best characterized as a toxic molecule rather than a specific inhibitor of glycolysis. Here, we identify the SLC16A1 gene product, monocarboxylate transporter 1 (MCT1), as the main determinant of 3-BrPA uptake and sensitivity, leading us to propose the therapeutic strategy of using MCT1-mediated transport to deliver toxic molecules to glycolytic tumors.
Gene-trap insertional mutagenesis in haploid or near-haploid metazoan cells has enabled genome-wide loss-of-function screens for genes underlying basic cellular physiology [25] [26] [27] . For example, screens in the near-haploid KBM7 human cell line identified the host factors necessary for the cytotoxic effects of several viruses and microbial toxins [28] [29] [30] . To apply this approach to the study of 3-BrPA, we used retroviral infection to create a library of mutagenized haploid KBM7 cells containing ~70 million insertions, which covered approximately 98% of all genes expressed in KBM7 cells 30 . The mutagenized cells were treated with 3-BrPA, and surviving cells were expanded as a pool. Using massively parallel sequencing, insertions in the resistant population were mapped to the human genome. Proximity index analysis was used to identify genomic regions that contained multiple gene-trap insertions in close proximity. SLC16A1 and BSG (encoding basigin) were the two most frequently inactivated genes ( Fig. 1a) and had the highest degree of insertional enrichment compared to the unselected control cells (P = 4.7 × 10 −121 and 5 × 10 −29 , respectively) ( Supplementary Fig. 1 ). The highest scoring gene, SLC16A1, encodes MCT1, an H + -linked monocarboxylate transporter that excretes lactate from cells and is highly upregulated in a subset of cancers [31] [32] [33] [34] [35] [36] . The second highest scoring gene, BSG, encodes a chaperone necessary for escorting MCT1 to the plasma membrane 37, 38 . To enable the in-depth study of the effects of MCT1 loss, we isolated two clones (clones A and B) that carried insertions in the first intron of the SLC16A1 gene (Fig. 1b) and in which MCT1 protein was undetectable by immunoblotting (Fig. 1c) . Consistent with the screening results, MCT1-null cells were completely resistant to doses of 3-BrPA (Fig. 1d ) that in parental KBM7 cells induced cell death accompanied by caspase-3 activation (Supplementary Fig. 1) . Notably, re-expression of MCT1 MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors 
there was no differences in lactate production or oxygen consumption between the cell types ( Supplementary Fig. 2 ), suggesting that MCT1 loss does not alter basal energy metabolism to any great extent. In contrast, 3-BrPA caused a substantial decrease in the extracellular acidification rate (ECAR), a proxy for lactate production, and total ATP levels (Fig. 2a,b) of parental but not MCT1-null KBM7 cells. Consistent with these findings, 3-BrPA did not affect AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) phosphorylation, markers of energy deficit 39 , in MCT1-null cells, whereas it robustly increased the presence of these markers in wild-type counterparts (Fig. 2b) . To more completely characterize the metabolic state of cells in response to 3-BrPA, we metabolically profiled wild-type and MCT1-null KBM7 cells treated with 3-BrPA.
Relative to MCT1-null cells, wild-type KBM7 cells treated with 3-BrPA showed an accumulation of the glycolytic intermediates that precede the synthesis of glyceraldehyde 3-phosphate, a substrate for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), but a depletion of those that are synthesized later. Furthermore, 3-BrPA-treated wild-type KBM7 cells accumulated intermediates of the pentose phosphate pathway, which branches off from glycolysis above the GAPDH-mediated step (Fig. 2c) . Additionally, the partial suppression by RNA interference (RNAi) of GAPDH expression slowed down cancer cell proliferation and sensitized cells to 3-BrPA treatment (Supplementary Fig. 3 ). 3-BrPA has previously been shown to inhibit GAPDH 17 , along with several other glycolytic enzymes, including hexokinase 2 (refs. [40] [41] [42] , lactate dehydrogenase 19 , succinate dehydrogenase 18, 43 , aldolase 44 and pyruvate kinase 45, 46 . However, our metabolite profiling strongly implicates GAPDH inhibition as the primary cause of the anti-glycolytic effects of 3-BrPA (Fig. 2c) . Altogether, these data show that MCT1-null KBM7 cells are resistant to the metabolic effects of 3-BrPA, suggesting that 3-BrPA might not enter cells in the absence of MCT1 and implicating MCT1 as a 3-BrPA transporter. Indeed, compared to parental KBM7 cells, MCT1-null cells did not take up [ 14 C]-labeled 3-BrPA (Fig. 2d) . Unlabeled 3-BrPA and, to a lesser extent, known MCT1 substrates, such as lactate and pyruvate, effectively competed with the uptake of radiolabeled 3-BrPA, showing that transport is specific (Supplementary Fig. 4) . Moreover, consistent with the pH dependence of MCT1-mediated transport 31, 47 , a reduction in extracellular pH enhanced 3-BrPA uptake (Supplementary Fig. 4) . Thus, MCT1 is necessary for the cellular uptake of 3-BrPA and, given its capacity to transport monocarboxylates 47 , probably directly transports 3-BrPA.
Considering that there are many MCTs and sodium-coupled monocarboxylate transporters (SMCTs) encoded in the human genome, we took an unbiased approach to ask whether MCT1 expression is the most predictive of 3-BrPA sensitivity. In a panel of 15 cancer cell lines, we determined half-maximal inhibitory concentration (IC 50 l e t t e r s (CCLE) 48 . Notably, of the 20,000 mRNAs examined, SLC16A1 mRNA levels were the single best predictor of 3-BrPA sensitivity (r = −0.89, P = 1.4 × 10 −5 ) (Fig. 3a) . Furthermore, the expression of no other member of the MCT and SMCT monocarboxylate transporter families was significantly correlated with the 3-BrPA sensitivity of cancer cell lines ( Fig. 3a and Supplementary Fig. 5 ). Another monocarboxylate transporter, Jen1p, was recently implicated as the primary carrier of 3-BrPA in yeast 49 ; however, this transporter bears no homology to any human gene product. We next asked whether MCT1 expression could also predict 3-BrPA sensitivity within a single cancer type, focusing on breast cancer lines because they exhibit a particularly wide range of MCT1 expression (Supplementary Fig. 6 ). Indeed, breast cancer lines with high amounts of MCT1 protein were sensitive to 3-BrPA, whereas those with low or no MCT1 expression were resistant to even high concentrations of 3-BrPA (Fig. 3b) . Stable expression of MCT1 in two breast cancer lines with low MCT1 expression (MDA-MB-231 and SK-BR-3) was sufficient to sensitize them to 3-BrPA (Fig. 3c) . As in KBM7 cells, MCT1 expression did not alter lactate production or oxygen consumption, but it did enhance uptake of [ 14 C]-labeled 3-BrPA (Fig. 3d) . Conversely, the partial suppression by RNAi of MCT1 expression was sufficient to confer resistance to 3-BrPA in cell lines with high levels of MCT1 (BT-20 and BT-549) (Fig. 3e) .
To test whether MCT1 expression could affect the sensitivity of established tumors to 3-BrPA, parental MDA-MB-231 cells, which express low levels of MCT1 (Supplementary Fig. 6 ), were injected subcutaneously into the left flanks of nude mice, while MDA-MB-231 cells stably expressing MCT1 were injected into the contralateral flanks of the same animals. We allowed palpable subcutaneous tumors to form for 2 weeks before beginning 3-BrPA administration. After 3 weeks of 3-BrPA treatment, tumors with forced MCT1 expression were significantly smaller than those that were untreated or treated with 3-BrPA but expressed control green fluorescent protein (GFP) (Fig. 3f  and Supplementary Fig. 6 ). These results indicate that MCT1 expression is sufficient to sensitize preformed tumors to 3-BrPA treatment and has predictive value for determining 3-BrPA sensitivity in vivo.
We additionally examined whether cancer cells with high levels of MCT1 expression shared any metabolic properties. Using the oxygen consumption rate (OCR) to ECAR ratio as a measure of the relative contributions of oxidative phosphorylation and glycolysis to cellular energy production, we compared OCR/ECAR ratios from 15 cancer cell lines with genome-wide expression data obtained from CCLE. Notably, along with two glycolytic enzymes (LDHB and PGM1), MCT1 was among the factors whose expression most strongly and significantly correlated with lower OCR/ECAR ratios (Fig. 4 and Supplementary  Fig. 6 ). This finding indicates that tumors that have the highest rates of glycolysis are more likely to have high MCT1 expression and therefore will be more sensitive to 3-BrPA treatment (Fig. 4) .
Our results predict that MCT1 expression will serve as a biomarker for identifying tumors likely to respond to 3-BrPA treatment 14, 15 . Furthermore, as we find that MCT1 expression correlates with elevated glycolysis, it may be possible to enhance the efficacy of 3-BrPA by concomitant treatment with glycolytic inhibitors so as to exploit the high glycolytic demand of tumors and the cancer-enriched expression of MCT1. It is noteworthy that small molecule inhibitors of MCT1 that inhibit lactate export from cancer cells are in development and show promise as anticancer therapies 11, 50 . Although this approach requires that MCT1 be expressed and essential for cancer cell survival 11,50 , 3-BrPA treatment is distinct in that it requires only MCT1 expression to be efficacious. For example, KBM7 cells are sensitive to 3-BrPA, but complete loss of MCT1 does not affect their viability.
Our data further suggest that the toxic effect of 3-BrPA is not a result of its anti-glycolytic effect but rather its highly alkylating nature. The stringent correlation between 3-BrPA sensitivity and expression of its transporter but not that of any previously identified metabolic targets or transporters 49, 51 suggests that 3-BrPA is likely nonspecifically toxic once it enters the cell. Consistent with this idea, 3-BrPA has non-glycolytic targets, such as V-ATPases 20 , sarcoplasmic reticulum Ca 2+ -ATPases (SERCAs) 24 , carbonic anhydrases 52 and histone deacetylases (HDACs) 53 . Like MCT1, other transporters are also upregulated in subsets of cancers 54, 55 , and it therefore may be possible to develop toxic molecules that, in a fashion analogous to 3-BrPA, exploit these transporters to selectively enter and target cancer cells.
MeTHOds
Methods and any associated references are available in the online version of the paper. 
